Rheumatoid Arthritis. XIII Diseases of the musculoskeletal system and connective tissue
Conditions
Interventions
Intervention 1: Intervention group: Atorvastatin (40 mg daily). Intervention 2: control group: placebo.
Treatment - Drugs
Placebo
Intervention group: Atorvastatin (40 mg daily)
control group: placebo
Sponsors
Vice Chancellor for research of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria are as follows: 1) meeting the 2010 ACR/EULAR criteria; 2) =18 years of age; and 3) DAS-28-ESR < 3.2. The exclusion criteria are : 1) known liver disease; 2) elevated transaminases two months before the study; 3) previous history of myopathy; 4) pregnancy; 5) breastfeeding; 6) use of lipid-lowering agents; and 7) being eligible for taking lipid-lowering agents according to the National Cholesterol Education Program (NCEP).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Activity Index. Timepoint: Before intervention, after 4 weeks, 8 weeks and 12 weeks. Method of measurement: Clinical.;Lipid profile. Timepoint: Before intervention, after 4 weeks, 8 weeks and 12 weeks. Method of measurement: Laboratory. | — |
Secondary
| Measure | Time frame |
|---|---|
| ESR. Timepoint: Before intervention, after 4 weeks, 8 weeks and 12 weeks. Method of measurement: Laboratory.;Hs-CRP. Timepoint: Before intervention, after 4 weeks, 8 weeks and 12 weeks. Method of measurement: Laboratory.;Liver function test. Timepoint: Before intervention, after 4 weeks, 8 weeks and 12 weeks. Method of measurement: Laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZhaleh Shariati
Mashhad University of Medical Sciences
Outcome results
None listed